Bullish indicating open at $55-$60, IPO prices at $37
Veradigm Inc., a company specializing in computer integrated systems design currently trading at $4.40 with a market capitalization of $747 million, has expanded its stock incentive plan, according to a recent SEC filing. According to InvestingPro data, the stock has experienced significant pressure, declining nearly 60% over the past six months. On May 20, 2025, the Board of Directors approved an amendment and restatement of the Veradigm Inc. 2024 Stock Incentive Plan, which now authorizes the issuance of an additional 6 million shares of common stock. This increase brings the total number of shares available for grants to 11 million under the 2024 Plan.
The 2024 Plan aims to align the interests of Veradigm’s stockholders with those receiving awards, attract and retain valuable personnel, and encourage actions in the long-term best interests of the company and its shareholders. Analysts tracked by InvestingPro have set price targets ranging from $4.50 to $15.00, suggesting potential upside despite recent market challenges. The plan allows for the granting of nonqualified stock options, stock appreciation rights, restricted stock and stock units, as well as performance units.
This information is based on the 8-K filing by Veradigm Inc. with the Securities and Exchange Commission. The details of the amended 2024 Plan are outlined in Exhibit 10.1 attached to the filing. Veradigm, formerly known as Allscripts (OTC:MDRX) Healthcare Solutions, Inc., is headquartered in Chicago, Illinois, and is incorporated in Delaware. The company trades under the ticker MDRX on the OTC Expert Market. InvestingPro analysis reveals additional insights about Veradigm’s financial health and market position, with several key metrics and investment considerations available in the comprehensive Pro Research Report, which provides detailed analysis of over 1,400 US stocks.
The SEC filing also includes the standard cover page interactive data file within the Inline XBRL document, listed as Exhibit 104. The signing of the report was executed on behalf of Veradigm Inc. by Eric Jacobson, Senior Vice President, Deputy General Counsel, and Corporate Secretary, on May 22, 2025.
In other recent news, Veradigm Inc. has reported its Q4 2024 financial results, showing stable revenue that aligned with market expectations. The company posted earnings per share of $0.3079, slightly below the projected $0.31, while revenue met forecasts at $168.7 million. Despite some revenue shortfalls in 2024, Veradigm maintained a strong net cash position of $87 million by year-end. The company anticipates flat revenue for 2025 compared to 2024 and continues to focus on cost optimization and AI-enabled solutions to enhance operational efficiency.
In another development, Veradigm appointed BDO USA, P.C. as its new independent registered public accountant, replacing Grant Thornton LLP. This change follows an adverse opinion from Grant Thornton on Veradigm’s internal control over financial reporting for the fiscal year ending December 31, 2022, due to identified material weaknesses. These weaknesses were related to various accounting and financial reporting processes. Veradigm is working to address these issues as part of its ongoing remediation plan.
Additionally, Veradigm’s strategic initiatives include expanding its provider base and enhancing its AI capabilities across its payer, provider, and life sciences segments. The company is also pursuing additional debt financing to support its strategic goals. Despite challenges, Veradigm remains committed to improving its financial reporting and operational practices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.